Esophageal and esophagogastric junction cancers, Version 2.2019

Jaffer A. Ajani; Thomas A. D'Amico; David J. Bentrem; Joseph Chao; Carlos Corvera; Prajnan Das; Crystal S. Denlinger; Peter C. Enzinger; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael Gibson; Robert E. Glasgow; James A. Hayman; Steven Hochwald; Wayne L. Hofstetter; David H. Ilson; Dawn Jaroszewski; Kimberly L. Johung; Rajesh N. Keswani; Lawrence R. Kleinberg; Stephen Leong; Quan P. Ly; Kristina A. Matkowskyj; Michael McNamara; Mary F. Mulcahy; Ravi K. Paluri; Haeseong Park; Kyle A. Perry; Jose Pimiento; George A. Poultsides; Robert Roses; Vivian E. Strong; Georgia Wiesner; Christopher G. Willett; Cameron D. Wright; Nicole R. McMillian; Lenora A. Pluchino

doi:10.6004/jnccn.2019.0033

Esophageal and esophagogastric junction cancers, Version 2.2019

Jaffer A. Ajani, Thomas A. D'Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. KeswaniLawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian, Lenora A. Pluchino

School of Medicine

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Abstract

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America andWestern Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced ormetastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

Original language	English (US)
Pages (from-to)	855-883
Number of pages	29
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2019.0033
State	Published - 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2019.0033

Cite this

Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., Gerdes, H., Gibson, M., Glasgow, R. E., Hayman, J. A., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Jaroszewski, D., Johung, K. L., ... Pluchino, L. A. (2019). Esophageal and esophagogastric junction cancers, Version 2.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(7), 855-883. https://doi.org/10.6004/jnccn.2019.0033

Ajani, JA, D'Amico, TA, Bentrem, DJ, Chao, J, Corvera, C, Das, P, Denlinger, CS, Enzinger, PC, Fanta, P, Farjah, F, Gerdes, H, Gibson, M, Glasgow, RE, Hayman, JA, Hochwald, S, Hofstetter, WL, Ilson, DH, Jaroszewski, D, Johung, KL, Keswani, RN, Kleinberg, LR, Leong, S, Ly, QP, Matkowskyj, KA, McNamara, M, Mulcahy, MF, Paluri, RK, Park, H, Perry, KA, Pimiento, J, Poultsides, GA, Roses, R, Strong, VE, Wiesner, G, Willett, CG, Wright, CD, McMillian, NR & Pluchino, LA 2019, 'Esophageal and esophagogastric junction cancers, Version 2.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 7, pp. 855-883. https://doi.org/10.6004/jnccn.2019.0033

@article{cf5d45accbf74c33868195df921976c0,

title = "Esophageal and esophagogastric junction cancers, Version 2.2019",

abstract = "Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America andWestern Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced ormetastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.",

author = "Ajani, {Jaffer A.} and D'Amico, {Thomas A.} and Bentrem, {David J.} and Joseph Chao and Carlos Corvera and Prajnan Das and Denlinger, {Crystal S.} and Enzinger, {Peter C.} and Paul Fanta and Farhood Farjah and Hans Gerdes and Michael Gibson and Glasgow, {Robert E.} and Hayman, {James A.} and Steven Hochwald and Hofstetter, {Wayne L.} and Ilson, {David H.} and Dawn Jaroszewski and Johung, {Kimberly L.} and Keswani, {Rajesh N.} and Kleinberg, {Lawrence R.} and Stephen Leong and Ly, {Quan P.} and Matkowskyj, {Kristina A.} and Michael McNamara and Mulcahy, {Mary F.} and Paluri, {Ravi K.} and Haeseong Park and Perry, {Kyle A.} and Jose Pimiento and Poultsides, {George A.} and Robert Roses and Strong, {Vivian E.} and Georgia Wiesner and Willett, {Christopher G.} and Wright, {Cameron D.} and McMillian, {Nicole R.} and Pluchino, {Lenora A.}",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2019",

doi = "10.6004/jnccn.2019.0033",

language = "English (US)",

volume = "17",

pages = "855--883",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

TY - JOUR

T1 - Esophageal and esophagogastric junction cancers, Version 2.2019

AU - Ajani, Jaffer A.

AU - D'Amico, Thomas A.

AU - Bentrem, David J.

AU - Chao, Joseph

AU - Corvera, Carlos

AU - Das, Prajnan

AU - Denlinger, Crystal S.

AU - Enzinger, Peter C.

AU - Fanta, Paul

AU - Farjah, Farhood

AU - Gerdes, Hans

AU - Gibson, Michael

AU - Glasgow, Robert E.

AU - Hayman, James A.

AU - Hochwald, Steven

AU - Hofstetter, Wayne L.

AU - Ilson, David H.

AU - Jaroszewski, Dawn

AU - Johung, Kimberly L.

AU - Keswani, Rajesh N.

AU - Kleinberg, Lawrence R.

AU - Leong, Stephen

AU - Ly, Quan P.

AU - Matkowskyj, Kristina A.

AU - McNamara, Michael

AU - Mulcahy, Mary F.

AU - Paluri, Ravi K.

AU - Park, Haeseong

AU - Perry, Kyle A.

AU - Pimiento, Jose

AU - Poultsides, George A.

AU - Roses, Robert

AU - Strong, Vivian E.

AU - Wiesner, Georgia

AU - Willett, Christopher G.

AU - Wright, Cameron D.

AU - McMillian, Nicole R.

AU - Pluchino, Lenora A.

PY - 2019

Y1 - 2019

N2 - Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America andWestern Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced ormetastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

AB - Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America andWestern Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced ormetastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

UR - http://www.scopus.com/inward/record.url?scp=85070074237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070074237&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0033

DO - 10.6004/jnccn.2019.0033

M3 - Article

C2 - 31319389

AN - SCOPUS:85070074237

SN - 1540-1405

VL - 17

SP - 855

EP - 883

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Esophageal and esophagogastric junction cancers, Version 2.2019

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this